AOD-9604 is a synthetic peptide consisting of the C-terminal fragment (amino acids 176-191) of human growth hormone. It was developed to capture the fat-burning properties of HGH without the blood sugar and insulin side effects associated with full-length growth hormone.

Does AOD-9604 really burn fat?

Preclinical studies in rodents show that AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat creation). However, human clinical trials have produced mixed results. A Phase IIb trial in obese patients did not meet its primary weight loss endpoint, though some secondary measures showed modest benefit.

Is AOD-9604 FDA approved?

No. AOD-9604 received GRAS (Generally Recognized as Safe) status from the FDA in 2014 for use in food, but it is not approved as a pharmaceutical for weight loss. It is sold as a research compound and in some supplement formulations.

What is the typical dose of AOD-9604?

Commonly used doses in clinical settings range from 300-500mcg daily via subcutaneous injection, typically administered in the morning on an empty stomach. However, there is no FDA-approved dosing protocol.

How does AOD-9604 compare to semaglutide for weight loss?

AOD-9604 and semaglutide work through completely different mechanisms and have vastly different levels of clinical evidence. Semaglutide has robust Phase III trial data showing 15-17% body weight loss, while AOD-9604 has limited human data showing modest effects at best. They are not in the same category of evidence.

AOD-9604: The Fat-Burning Peptide Fragment — Mechanism, Evidence & Safety

In the search for weight loss compounds that don't carry the baggage of full growth hormone therapy, AOD-9604 has carved out an interesting niche. Originally developed by researchers at Monash University in Australia, this 15-amino-acid fragment of human growth hormone (HGH) promised to isolate the fat-burning signal while discarding the problematic metabolic effects.

The question is whether it delivers on that promise.

What Is AOD-9604?

AOD-9604 is a modified form of the C-terminal fragment of human growth hormone, specifically amino acids 176-191. The "modification" is a tyrosine added at the N-terminus to enhance stability. The result is a peptide that's roughly 1/10th the size of full HGH but retains certain lipolytic (fat-breaking) properties.

The original hypothesis was elegant: HGH causes fat loss, but it also raises blood sugar, promotes insulin resistance, and can cause acromegaly with chronic use. If you could isolate just the part of the molecule responsible for fat metabolism, you'd have a weight loss tool without the side effects.

Molecular Mechanism

AOD-9604 appears to work through several pathways:

Mechanism	Description	Evidence Level
Beta-3 adrenergic activation	Stimulates fat breakdown in adipocytes via β3-AR signaling	Preclinical (rodent)
Anti-lipogenic effect	Inhibits synthesis of new fatty acids in liver and adipose tissue	Preclinical
AMPK activation	May enhance cellular energy sensing and fat oxidation	Preclinical
HGH receptor independent	Does not bind the GH receptor or stimulate IGF-1	Confirmed in human studies

Importantly, AOD-9604 does not appear to bind the growth hormone receptor, which means it shouldn't cause the blood sugar dysregulation, joint pain, or organ enlargement associated with exogenous HGH. Studies confirmed it doesn't elevate IGF-1 levels.

The Clinical Evidence

This is where the story gets complicated.

Preclinical Data (Strong)

In rodent studies, AOD-9604 showed compelling results:

Obese rats treated with AOD-9604 lost significantly more body fat than controls (Ng et al., 2000)
The peptide appeared to preferentially target visceral fat — the metabolically dangerous fat around internal organs
Fat loss occurred without decreased food intake, suggesting a direct metabolic effect
No adverse effects on blood glucose or insulin sensitivity were observed

Human Data (Mixed)

The transition from rats to humans was less encouraging.

Phase IIb Clinical Trial (2013): Metabolic Pharmaceuticals conducted a large randomized controlled trial in obese patients. The primary endpoint — statistically significant weight loss versus placebo — was not met. However:

Some secondary endpoints showed trends toward fat reduction
The peptide was well-tolerated with a clean safety profile
Post-hoc analyses suggested certain subgroups may have responded better

Other studies: Small open-label studies have shown modest reductions in body fat percentage and waist circumference, but these lack the rigor of placebo-controlled trials.

Why the Disconnect?

Several factors may explain why preclinical promise didn't translate cleanly to human efficacy:

Dosing challenges — Optimal human dosing may differ significantly from rodent dosing
Bioavailability — Subcutaneous injection may not achieve adequate tissue concentrations
Study duration — Longer trials might be needed to see meaningful fat loss
Population effects — AOD-9604 may work better in certain metabolic profiles

AOD-9604 vs. Other Weight Loss Peptides

Feature	AOD-9604	Semaglutide	Tirzepatide	Tesamorelin
Mechanism	GH fragment, lipolysis	GLP-1 receptor agonist	GLP-1/GIP dual agonist	GHRH analog
FDA approved for weight loss	No	Yes (Wegovy)	Yes (Zepbound)	No (HIV lipodystrophy only)
Typical weight loss	Modest (limited data)	15-17% body weight	20-22% body weight	15-20% visceral fat reduction
IGF-1 impact	None	None	None	Elevated
Blood sugar impact	Neutral	Improved	Improved	Neutral to mildly elevated
Appetite suppression	Minimal	Significant	Significant	Minimal
Evidence quality	Low (mostly preclinical)	High (Phase III RCTs)	High (Phase III RCTs)	Moderate (Phase III for HIV)
Route	SubQ injection	SubQ injection	SubQ injection	SubQ injection

For patients considering peptides for weight loss, AOD-9604 occupies an interesting but evidence-limited position. It lacks the dramatic efficacy of semaglutide or tirzepatide, but it also lacks their gastrointestinal side effects.

Safety Profile

AOD-9604's safety profile is one of its stronger points:

No IGF-1 elevation — eliminates the cancer and acromegaly concerns of full HGH
No blood sugar disruption — unlike growth hormone, it doesn't appear to worsen insulin sensitivity
No reported serious adverse events in clinical trials
Mild injection site reactions — the most common complaint
Long-term data lacking — most studies have been 12-24 weeks

The GRAS designation from the FDA in 2014 was based on a review of toxicology data, which showed no significant safety concerns at intended doses.

Practical Considerations

For clinicians and patients who do choose to use AOD-9604:

Dosing Protocol

Typical dose: 300-500mcg daily
Route: Subcutaneous injection
Timing: Morning, ideally on an empty stomach (30-60 minutes before eating)
Cycle length: 8-12 weeks common, with 4-week breaks
Storage: Refrigerated after reconstitution

What to Expect

Set appropriate expectations based on the evidence:

Primary benefit: Modest reduction in body fat percentage over weeks to months
Not a substitute for caloric deficit and exercise
Works best as an adjunct to lifestyle interventions
Visceral fat may respond preferentially based on preclinical data
Timeline: Any effects are gradual — expect 8-12 weeks minimum

Who Might Consider It

Patients who cannot tolerate GLP-1 agonists due to GI side effects
Individuals seeking modest fat loss support alongside diet and exercise
Those interested in the visceral fat-reduction properties
Patients in peptide stacking protocols (see weight loss peptide stack guide)

Current Research Landscape

Active research areas include:

Combination protocols — AOD-9604 paired with GLP-1 agonists to target different fat loss pathways
Optimal dosing studies — exploring whether higher or more frequent doses improve efficacy
Subpopulation analysis — identifying which metabolic profiles respond best
Visceral fat imaging — using DEXA and MRI to quantify regional fat changes

The peptide remains of interest precisely because its safety profile is clean. If researchers can solve the dosing and delivery puzzle, it could complement rather than compete with the GLP-1 revolution.

The Bottom Line

AOD-9604 is a well-designed peptide with a strong theoretical basis and a clean safety profile. Its preclinical data is genuinely promising, showing selective fat reduction without the metabolic downsides of full growth hormone.

But the human clinical data is underwhelming compared to what we've seen from GLP-1 receptor agonists. The Phase IIb trial's failure to meet its primary endpoint is a significant mark against it.

If you're choosing a peptide for weight loss based on evidence, semaglutide and tirzepatide are in a completely different league. AOD-9604 may have a role as an adjunctive therapy or for patients who can't tolerate the alternatives, but it shouldn't be anyone's primary fat loss strategy.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. AOD-9604 is not FDA-approved for weight loss. Always consult a qualified healthcare provider before starting any peptide therapy. Individual results may vary.